Bangladesh Complains of Flood Of Adulterated Drugs From Drug Firms
This article was originally published in PharmAsia News
Executive Summary
Bangladesh authorities report that of 250 drugs licensed in the country, 200 are sub-standard even though they are made by recognized drug companies. The Directorate of Drug Administration says as a result, the country has a market flooded with adulterated medicines. Attorneys challenging that view note the nation has only one drug court that remains idle along with the DDA and other authorities. A total of 25 children recently were reported to have died after receiving a paracetamol syrup made by Rid Pharmaceutical, whose drug later was determined to contain a toxic ingredient. (Click here for more
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.